← Pathophysiology library
Clinician view

Pathophysiology

Hepatitis C

The Fibrotic Hijack: How HCV Rebrands the Liver

You have a virus that doesn't just occupy hepatocytes; it converts them into viral factories and then invites the immune system to burn the whole factory down. To stop the progression to cirrhosis, you have to interrupt the viral assembly line before the structural remodeling becomes irreversible.

The central question: How does viral replication trigger the structural death of the liver?

01

How it works — the zoom from whole body to molecule

System to cell

  1. 1

    System

    the whole body at work

    • In a healthy state, hepatocytes are the metabolic powerhouses of the body, organized into functional lobules that process nutrients and detoxify the blood.
    • They are responsible for the massive synthetic output of albumin and clotting factors that maintain your oncotic pressure and your ability to stop bleeding.
    • The space of Disse remains clear, allowing for seamless exchange between the bloodstream and the cells.
    • This delicate balance is regulated by a steady flow of portal blood and biliary drainage.
  2. 2

    Organ

    the healthy sequence, step by step

    • Hepatocyte protein synthesis (Albumin/Clotting Factors)
    • Sinusoidal filtration of toxins
    • Biliary excretion of waste
    • Maintenance of low-pressure portal flow
  3. 3

    Tissue & mechanism

    where and why it breaks

    • The HCV life cycle is a high-speed assembly line that depends on specific viral proteins to replicate.
    • By understanding this line, you can see exactly where modern Direct-Acting Antivirals (DAAs) throw a wrench into the works.
    • The virus enters, uncoats, and then uses NS3/4A protease to snip its large polyprotein into functional pieces, NS5B to copy its RNA blueprint, and NS5A to organize the final assembly of new viral particles.
  4. 4

    Cell & molecule

    the break at its smallest scale

    • NS3/4A Protease cleavage of the viral polyprotein
    • NS5B RNA-dependent RNA polymerase replication of the genome
    • NS5A-mediated viral assembly and secretion
    • Triggering of the TGF-beta pathway in Stellate Cells
    • Progressive collagen cross-linking (remodeling the architecture)
  5. 5

    The result

    what the break produces

    • Viral RNA hijacking of the hepatocyte protein-synthesis machinery
    • Immune-mediated hepatocyte apoptosis
    • Activation of Hepatic Stellate Cells into myofibroblasts
    • Deposition of collagen in the Space of Disse (Fibrosis)
02

How it works when healthy

Normal anatomy & physiology

  • In a healthy state, hepatocytes are the metabolic powerhouses of the body, organized into functional lobules that process nutrients and detoxify the blood.
  • They are responsible for the massive synthetic output of albumin and clotting factors that maintain your oncotic pressure and your ability to stop bleeding.
  • The space of Disse remains clear, allowing for seamless exchange between the bloodstream and the cells.
  • This delicate balance is regulated by a steady flow of portal blood and biliary drainage.

The healthy sequence

  1. 1Hepatocyte protein synthesis (Albumin/Clotting Factors)
  2. 2Sinusoidal filtration of toxins
  3. 3Biliary excretion of waste
  4. 4Maintenance of low-pressure portal flow
03

Why it breaks

The mechanism

  • The HCV life cycle is a high-speed assembly line that depends on specific viral proteins to replicate.
  • By understanding this line, you can see exactly where modern Direct-Acting Antivirals (DAAs) throw a wrench into the works.
  • The virus enters, uncoats, and then uses NS3/4A protease to snip its large polyprotein into functional pieces, NS5B to copy its RNA blueprint, and NS5A to organize the final assembly of new viral particles.

Step by step

  1. 1NS3/4A Protease cleavage of the viral polyprotein
  2. 2NS5B RNA-dependent RNA polymerase replication of the genome
  3. 3NS5A-mediated viral assembly and secretion
  4. 4Triggering of the TGF-beta pathway in Stellate Cells
  5. 5Progressive collagen cross-linking (remodeling the architecture)
04

The failure chain

Pathophysiology of dysfunction

  • The shift starts when the Hepatitis C virus (HCV) enters the hepatocyte and uses the cell's own machinery to replicate its RNA.
  • This isn't just a quiet occupation; the presence of viral proteins triggers a chronic, smoldering immune response where CD8+ T-cells attack the infected hepatocytes.
  • This persistent 'friendly fire' leads to necroinflammation, which is the signal for the liver's repair crew—the stellate cells—to go into overdrive.

The first thing to break

Viral RNA hijacking of the hepatocyte protein-synthesis machinery

The cascade, in order

  1. 1Immune-mediated hepatocyte apoptosis
  2. 2Activation of Hepatic Stellate Cells into myofibroblasts
  3. 3Deposition of collagen in the Space of Disse (Fibrosis)
  4. 4Increased resistance to portal blood flow (Portal Hypertension)
05

Normal → Compensation → Decompensation → Failure

The full arc

1

Compensated

What you see

  • Normal Albumin/INR
  • No physical signs (asymptomatic)
  • Slightly elevated LFTs

What fools you

The patient feels totally fine and their labs might look 'boring,' but the stellate cells are silently building a wall of collagen.

2

Decompensated

What you see

  • Jaundice
  • Ascites
  • Scleral icterus
3

Failure

What you see

  • Encephalopathy
  • Variceal Bleeding
  • Hepatorenal Syndrome

What dies

The portal pressure is too high and the liver can't clear toxins (ammonia), leading to systemic collapse and multi-organ failure.

06

Tied to the mechanism

Why the symptoms appear

The chain that produces them

  1. 1Immune-mediated hepatocyte apoptosis
  2. 2Activation of Hepatic Stellate Cells into myofibroblasts
  3. 3Deposition of collagen in the Space of Disse (Fibrosis)
  4. 4Increased resistance to portal blood flow (Portal Hypertension)

What surfaces at each stage

Compensated

  • Normal Albumin/INR
  • No physical signs (asymptomatic)
  • Slightly elevated LFTs

Decompensated

  • Jaundice
  • Ascites
  • Scleral icterus

Failure

  • Encephalopathy
  • Variceal Bleeding
  • Hepatorenal Syndrome
07

Each drug → the exact broken step it fixes

What the medications do

NS3/4A Protease Inhibitors (e.g., Glecaprevir)

interrupts: Viral polyprotein processing
  • These act as the 'scissors-guard,' preventing the virus from cutting its long protein chain into the functional tools it needs to survive.
  • Without these cuts, the virus is essentially born with its hands tied.
  • Do not use these in patients with Child-Pugh B or C because the drug levels can become toxic as liver function fails.

NS5A Inhibitors (e.g., Velpatasvir)

interrupts: Viral assembly and secretion
  • This interrupts the 'foreman' of the viral factory, stopping the virus from organizing its RNA and proteins into a shippable package.
  • It breaks the assembly line at the final stage.
  • These are the backbone of pangenotypic regimens because they are highly potent against most HCV variants.

NS5B Polymerase Inhibitors (e.g., Sofosbuvir)

interrupts: RNA replication
  • This is a chain-terminator that mimics the building blocks of RNA; the virus tries to use it to copy its genome, but it hits a dead end.
  • It effectively jams the copying machine.
  • It is a 'nucleotide analog' and is the cornerstone of most modern curative 'one-pill' regimens.

Ribavirin

interrupts: Viral RNA synthesis and mutagenesis
  • An older-school move that creates so many mutations in the viral genome that the virus essentially 'mutates to death.' We use this now only in the toughest cases—usually when previous DAA therapy has failed or in complex cirrhosis cases.
  • Watch for hemolytic anemia; it's a known side effect that can tank your patient's H&H.

HAV/HBV Vaccinations

interrupts: Synergistic hepatocyte damage
  • This isn't for HCV itself, but to prevent 'second hits' to an already stressed liver.
  • Getting a second viral hepatitis on top of HCV is the fast track to liver failure.
  • Every clinician should ensure their HCV patient is immune to the other 'letters' in the hepatitis alphabet.
08

Confirm it, track it, act on it

Labs & outcomes

  • Serologies identify the virus + confirm acuity.
Hepatitis serologies (HAV IgM, HBsAg + IgM anti-HBc, anti-HCV, HCV RNA, HEV)Specific patterns for each

Identifies virus

LFTs (AST, ALT, alk phos, bilirubin)ALT often >1000 in acute

Hepatocellular pattern severity

INR + albuminMarkers of severity

Synthetic function

CBC + BMPStandard workup

Anemia, AKI

HIV testingAlters management

Co-infection (especially HCV)

Acetaminophen levelMajor reversible mimic

Concurrent toxicity

Interventions

Supportive care (rest, hydration, avoid hepatotoxins)All acute viral hepatitis

Foundation

Antivirals for severe acute HBV (entecavir, tenofovir)Severe acute or fulminant HBV

Reduces chronicity risk

Direct-acting antivirals for acute HCVWithin 6 months

Sofosbuvir + velpatasvir 12 weeks

Avoid alcohol + acetaminophen >2g/dayAll viral hepatitis

Hepatotoxic

Post-exposure prophylaxis for HAV/HBV contactsRecent exposure

Vaccine + Ig

Liver transplant evaluationFulminant hepatitis (King's criteria)

Lifesaving

Public health reportingAll confirmed cases

Required

Long-term monitoring for chronicity (HBV, HCV)All HBV/HCV

30-50% become chronic

What this means at the bedside

Anticipate: Screen every adult at least once (per CDC guidelines) because curative treatment prevents the transition from 'viral factory' to 'cirrhotic rock.'

Watch for: A sudden drop in platelets or a new-onset umbilical hernia, which signals the shift from compensated to portal hypertension.

Uncertainty: While DAAs offer a 95%+ cure rate, the long-term regression of advanced fibrosis after cure is still a variable, patient-specific process.

← Back to the Pathophysiology library

Educational use onlyThis system is for educational and clinical decision-support purposes only. It does not provide medical advice, diagnosis, or treatment. Crisis supportPrivacyTerms

Adapted with permission from the Clinical Reasoning Loop™, part of the Think Like a Provider™ Clinical Reasoning System by Jennawè Whitley, APRN, FNP-BC, NP-C. © Capital Covenant Enterprise LLC.

Install Maldek CHIN as an app — studies work even offline